Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue.

This was the first of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study enrolling approximately 510 patients at more than 60 clinical sites who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

Recently the Company announced that more than 133 patients have been enrolled in its MAESTRO-03 trial. An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... 2015 The surging prevalence of ... fuelled social media growth, with over 50% of ... social networking. Insurance companies are making use of ... and promote a diversity of their services and ... exploiting social networking services as part of sales ...
(Date:3/25/2015)... , March 25, 2015 Accelovance, a therapeutically ... finalist for "Best Contract Research Organization" at the upcoming ... Vaccine Congress. This is the eighth ... for the award, winning for "Best Contract Research Organization" ... Recommended" distinction in 2013. "We,re excited to ...
(Date:3/25/2015)... 2015  Point-of-Care Partners, a leading health information ... launched the ePrescribing State Law Capsule -- a ... regulatory requirements in all 50 states and DC.  ... to change rapidly, so we have evolved our ... ultimately patients, need," said Tony Schueth , ...
(Date:3/25/2015)... 2015 Researchers at Ancon Medical ... that will enable broader and less invasive screening ... a simple breath screen. The Minnesota-based medical device ... and Drug Administration (FDA) approval process and is ... Nanoparticle Biomarker Tagging device. , Ancon Medicals nanoparticle ...
Breaking Biology Technology:Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Point-of-Care Partners Launches the ePrescribing State Law Capsule 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... ... and cytokine-related research tips and information. , ... Piscataway, NJ (PRWEB) May 20, 2010 -- ... the world’s leading interferon expert for life science researchers, has launched a revamped ...
... , CAMBRIDGE, Mass. , May 19 Idenix Pharmaceuticals, Inc. (Nasdaq: ... the 2010 Citi Annual Global Health Care Conference on Wednesday, May 26, 2010 ... New York City and at the Jefferies 2010 Global Life Sciences Conference on ... Hyatt hotel, New York City . , ...
... May 19, 2010 Amsterdam Molecular,Therapeutics (EuroNext Amsterdam: AMT), ... non-audited business update in compliance with,the EU transparency directive. This report ... 2010. , , Q1 2010 Highlights, ... - Dossier validated by EMA on January 20, 2010, ...
Cached Biology Technology:Web Resource for Interferon Research 2Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 2AMT Provides Business Update for the First Quarter 2010 2AMT Provides Business Update for the First Quarter 2010 3
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... A joint study published in Cell by ... for Research in Biomedicine (IRB Barcelona) and the Institute ... Dolf Weijers at the University of Wageningen, in the ... called auxins activate multiple vital plant functions through various ...
... This news release is available in German . ... the death of thousands of neurons in the brain. Nerve growth ... of the neurons; however, clinical tests with GDNF have not yielded ... Neurobiology in Martinsried and their colleagues have now succeeded in demonstrating ...
... of Vitamin A used by teenagers to combat acne might ... an international team of researchers have found that it may ... with autoimmune disorders or those who have received transplants. This ... Journal of Leukocyte Biology . "The ...
Cached Biology News:Scientists unveil a molecular mechanism that controls plant growth and development 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3Vitamin A used in acne medicines may help autoimmune and transplant patients 2
...
... The new IKATUBE ULTRA TURRAX Tube Disperser ... closed homogenizing system. It offers a cleaner, safer, ... IKATUBE system processes sample volumes from 2 to ... sample type, researchers can choose one of 4 ...
...
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
Biology Products: